News

1. Bioclinica, Inc. To Demonstrate Technology-Enhanced Capabilities At Upcoming Global Industry Events 4/2/2013

   BioClinica, Inc. a global provider of clinical trial management solutions, recently announced that members of its team will attend, participate in, and speak at several upcoming industry conferences in April, May, and June.

2. DiaMedica Successfully Completes DM-199 cGMP Manufacturing And Pre-Clinical Toxicology Safety Studies 1/29/2013

   DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of DM-199 to be utilized in upcoming clinical trials.

3. ERT Expands Corporate Presence In Japan 1/15/2013

   ERT, a global technology-driven provider of health outcomes research services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), recently announced significant milestones that reinforce its position as a leading eClinical trial solutions provider in Japan.

4. A Collaboration For More Effective Centralized Cardiac Safety Services 12/3/2012

   Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for centralized cardiac safety services for select pharmaceutical clients.

5. Spaulding Clinical Research Announces Collaboration With Blinded Diagnostics For Centralized Cardiac Safety Services For Select Pharmaceutical Clients 12/3/2012

   Spaulding Clinical Research has agreed to offer ECG services using the new Spaulding webECG Diagnostic ECG Management system for late stage clinical trials through Blinded Diagnostics.

6. ERT Introduces An Enhanced Platform To Streamline Data Collection, Analysis And Processing In Clinical Trials 8/28/2012

   ERT, a global technology-driven provider of health outcomes services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), recently announced the launch of an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials. 

7. Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival 5/22/2012

   Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar^® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

8. iCardiac Technologies' Growth Accelerates Revenue Growth Exceeds 140% Supported By Expansion Of Operations 4/22/2012

   iCardiac Technologies, Inc., a provider of next  generation cardiac core lab services, announced recently it has recorded another increase in  its growth rate.

9. ERT And UCLA Initiate Innovative Pilot Program For Chronically Ill Patients 2/9/2012
   ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study in collaboration with UCLA, an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD).
10. Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors 1/10/2012
    Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.